Justin Kim
Stock Analyst at Oppenheimer
(0.96)
# 3,759
Out of 4,944 analysts
36
Total ratings
39.29%
Success rate
-12.68%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Justin Kim
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APLS Apellis Pharmaceuticals | Maintains: Outperform | $65 → $40 | $26.58 | +50.49% | 6 | Nov 6, 2024 | |
| PHVS Pharvaris | Maintains: Outperform | $38 → $42 | $21.43 | +95.99% | 4 | Sep 6, 2024 | |
| CYTK Cytokinetics | Maintains: Outperform | $107 → $106 | $36.88 | +187.42% | 5 | May 9, 2024 | |
| IMCR Immunocore Holdings | Reiterates: Outperform | $85 → $87 | $33.00 | +163.64% | 5 | Feb 29, 2024 | |
| VERA Vera Therapeutics | Initiates: Outperform | $26 | $21.97 | +18.34% | 1 | Jan 25, 2024 | |
| ALDX Aldeyra Therapeutics | Downgrades: Perform | n/a | $5.37 | - | 2 | Oct 17, 2023 | |
| ZURA Zura Bio | Initiates: Outperform | $17 | $1.59 | +969.18% | 1 | Aug 25, 2023 | |
| AUPH Aurinia Pharmaceuticals | Downgrades: Perform | n/a | $12.01 | - | 6 | Nov 4, 2022 | |
| BCRX BioCryst Pharmaceuticals | Downgrades: Perform | n/a | $8.53 | - | 5 | Aug 8, 2022 | |
| IONS Ionis Pharmaceuticals | Assumes: Outperform | $59 | $43.10 | +36.89% | 1 | Jul 18, 2022 |
Apellis Pharmaceuticals
Nov 6, 2024
Maintains: Outperform
Price Target: $65 → $40
Current: $26.58
Upside: +50.49%
Pharvaris
Sep 6, 2024
Maintains: Outperform
Price Target: $38 → $42
Current: $21.43
Upside: +95.99%
Cytokinetics
May 9, 2024
Maintains: Outperform
Price Target: $107 → $106
Current: $36.88
Upside: +187.42%
Immunocore Holdings
Feb 29, 2024
Reiterates: Outperform
Price Target: $85 → $87
Current: $33.00
Upside: +163.64%
Vera Therapeutics
Jan 25, 2024
Initiates: Outperform
Price Target: $26
Current: $21.97
Upside: +18.34%
Aldeyra Therapeutics
Oct 17, 2023
Downgrades: Perform
Price Target: n/a
Current: $5.37
Upside: -
Zura Bio
Aug 25, 2023
Initiates: Outperform
Price Target: $17
Current: $1.59
Upside: +969.18%
Aurinia Pharmaceuticals
Nov 4, 2022
Downgrades: Perform
Price Target: n/a
Current: $12.01
Upside: -
BioCryst Pharmaceuticals
Aug 8, 2022
Downgrades: Perform
Price Target: n/a
Current: $8.53
Upside: -
Ionis Pharmaceuticals
Jul 18, 2022
Assumes: Outperform
Price Target: $59
Current: $43.10
Upside: +36.89%